Navigation Links
CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
Date:5/11/2011

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received.

CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been used as an antibacterial agent previously. CG400549 is being developed to target the notorious resistant bacterial strains such as MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus). CG400549 had successfully completed the Phase I Single Ascending Dose Study in Europe last year and has just received the draft CSR for the Phase I MAD study.

The objective of the MAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of multiple ascending doses of CG400549 in healthy volunteers and a Phase IIa proof-of-concept study is anticipated to initiate as soon as the CSR is finalized.  

CG400549 has displayed remarkable in vitro and in vivo efficacy against some of the gold standard "superbug" therapeutics including Zyvox® and vancomycin as it demonstrated 4 to 8 fold better MICs, respectively. Prior to initiating clinical studies, several in vitro efficacy experiments were conducted at the laboratories of prominent infectious disease clinicians including Dr. Peter Applebaum's lab at the Hershey Medical Center.

Antibacterial resistance is a serious global health issue and one of the main culprits is the infections caused by Staphylococcus aureus such as MRSA. The number of MRSA infections in the United States has been increasing significantly as a 2007 report in Emerging Infectious Diseases, a publication of the Centers for Disease Control and Prevention (CDC), estimated the number of MRSA infections in hospitals doubled nationwide, from approximately 127,000 in 1999 to 278,000 in 2005, while at the same time annual deaths increased from 11,000 to more than 17,000. This is why there has been and will continue to be, a steady demand for novel class of antibiotics such as CG400549.

CrystalGenomics' dedication in combating infectious diseases has been evident in a number of occasions including its recent accomplishment of solving the 3 dimensional structure of the New Delhi metallo-beta-lactamase-1 (NDM-1), an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics which recently resurfaced in India and multiple countries worldwide. Also, in addition to CG400549 program, CrystalGenomics has several active discovery programs in infectious disease area. CrystalGenomics' capability in discovery and development of anti-infective drugs has been validated last year when it announced that it had entered into an R&D collaboration with AstraZeneca for novel anti-infectives.

References:

Klein E, Smith DL, Laxminarayan R (2007). "Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999–2005." Emerg Infect Dis 13 (12): 1840–6

Media Contact:
Steven Kim
CrystalGenomics, Inc.
+82-2-3010-8611
skim@cgxinc.com


'/>"/>
SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 LabStyle ... Dario™ Diabetes Management Tool, today announced that the Company,s Chief ... Marcum MicroCap Conference being held June 1-2 in ... being held June 7-9 in Los Angeles, CA. ... discuss recent corporate and operational milestones, including the U.S. FDA ...
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... 2016 According to a new market ... - U.S. Industry Analysis, Size, Share, Growth, Trends, and Forecast ... U.S. was valued at US$ 5.89 Bn in 2014 and ... 2015 to 2023 to reach US$ 7.99 Bn in 2023. ... emerging needle free drug delivery devices and the market is ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... to students studying complementary medicine. Allison Outerbridge is this year’s Life University ... on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... New Hampshire (PRWEB) , ... May 26, 2016 , ... ... skin care products, has been honored with a 2016 When Work Works Award for ... prestigious award, part of the national When Work Works project administered by the Families ...
Breaking Medicine News(10 mins):